Summit Therapeutics to Present at 18th Annual BIO CEO & Investor Conference
February 03 2016 - 7:00AM
Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug
discovery and development company advancing therapies for Duchenne
muscular dystrophy and Clostridium difficile infection, announces
that Mr Glyn Edwards, Chief Executive Officer, will present at the
18th Annual BIO CEO & Investor Conference, 9 February 2016 at
11:00am EST in New York City.
A live audio webcast of the presentation will be
available through the Investors section on the Company’s website,
www.summitplc.com. A replay of the webcast will be available soon
after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease DMD and the infectious disease Clostridium
difficile infection. Further information is available at
www.summitplc.com and Summit can be followed on Twitter
(@summitplc).
For more information, please contact:
|
|
|
|
|
|
Summit Glyn Edwards / Richard Pye
(UK office)Erik Ostrowski / Michelle Avery (US office) |
|
|
|
|
Tel: +44 (0)1235 443 951 +1 617 225 4455 |
Cairn Financial Advisers LLP(Nominated
Adviser)Liam Murray / Tony Rawlinson |
|
|
|
|
Tel: +44 (0)20 77148 7900 |
N+1 Singer (Broker)Aubrey Powell / Jen
Boorer |
|
|
|
|
Tel: +44 (0)20 7496 3000 |
Peckwater PR(Financial public relations,
UK)Tarquin Edwards |
|
|
|
|
Tel: +44
(0)7879 458 364 tarquin.edwards@peckwaterpr.co.uk |
MacDougall Biomedical Communications(US media
contact)Chris Erdman |
|
|
|
|
Tel: +1
781 235 3060cerdman@macbiocom.com |
|
|
|
|
|
|
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024